DDDouglas R. Davies

Douglas R. Davies

*This is an algorithmically generated author record based on publicly available information.

Douglas R. Davies has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda L. Rychel

    Department of Biology, University of Washington, Seattle, WA 98195-1800, USA

    1 shared publication
  • Bart L. Staker

    Center for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA

    1 shared publication
  • Hidong Kim

    Seattle Structural Genomics Center for Infectious Disease (http://www.ssgcid.org), USA

    1 shared publication
  • Jan A. Abendroth

    Seattle Structural Genomics Center for Infectious Disease (http://www.ssgcid.org), USA

    1 shared publication
  • Jess Leonard

    Seattle Structural Genomics Center for Infectious Disease (http://www.ssgcid.org), USA

    1 shared publication
  • Lance J. Stewart

    Seattle Structural Genomics Center for Infectious Disease (http://www.ssgcid.org), USA

    1 shared publication

Latest Publications

  • Screening Ligands by X-ray Crystallography

    by Douglas R. Davies

    X-ray crystallography is an invaluable technique in structure-based drug discovery, including fragment-based drug discovery, because it is the only technique that can provide a complete three dimensional readout of the interaction between the small molecule and its macromolecular target. X-ray diffraction (XRD) techniques can be employed as the sole method for conducting a screen of a fragment library, or it can be employed as the final technique in a screening campaign to confirm putative “hit” compounds identified by a variety of biochemical and/or biophysical screening techniques. Both approaches require an efficient technique to prepare dozens to hundreds of crystals for data collection, and a reproducible way to deliver ligands to the crystal. Here, a general method for screening cocktails of fragments is described. In cases where X-ray crystallography is employed as a method to verify putative hits, the cocktails of fragments described below would simply be replaced with single fragment solutions.


  • Open Access

    An ensemble of structures ofBurkholderia pseudomallei2,3-bisphosphoglycerate-dependent phosphoglycerate mutase

    by Douglas R. Davies, Bart L. Staker, Jan A. Abendroth, Thomas E. Edwards, Robert Hartley, Jess Leonard, Hidong Kim, Amanda L. Rychel, Stephen N. Hewitt, Peter J. Myler, et al.

    Burkholderia pseudomallei is a soil-dwelling bacterium endemic to Southeast Asia and Northern Australia. Burkholderia is responsible for melioidosis, a serious infection of the skin. The enzyme 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (PGAM) catalyzes the interconversion of 3-phosphoglycerate and 2-phosphoglycerate, a key step in the glycolytic pathway. As such it is an extensively studied enzyme and X-ray crystal structures of PGAM enzymes from multiple species have been elucidated. Vanadate is a phosphate mimic that is a powerful tool for studying enzymatic mechanisms in phosphoryl-transfer enzymes such as phosphoglycerate mutase. However, to date no X-ray crystal structures of phosphoglycerate mutase have been solved with vanadate acting as a substrate mimic. Here, two vanadate complexes together with an ensemble of substrate and fragment-bound structures that provide a com­prehensive picture of the function of the Burkholderia enzyme are reported.